Review Article
Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
Table 2
Summary of neoadjuvant bevacizumab-based chemotherapy trials.*
| Clinical trials | Design | Drugs | Population | Status | pCR rate |
| Gerber et al. [31] (GeparQuinto) | Phase III | Arm 1: EC × 4 → D × 4 Arm 2: EC+ Bev × 4 → D + Bev × 4 | TNBC | Completed | Arm 1: 96/342 (28%) Arm 2: 119/327 (36.4%) |
| Bear et al. [14] (NSABP B-40) | Phase III random | Arm 1A-C: Anthracycline-taxane-based chemotherapy Arm 2A-C: Anthracycline-taxane-based chemotherapy + Bev | HER2− | Completed | All Arms Bev: 203/588 (35%) All Arms/no Bev: 168/592 (28%) TNBC Bev: 121/236 (51%) TNBC/no Bev: 115/243 (47%) HR+ Bev: 82/352 (23%) HR+/no Bev: 53/349 (15%) |
| CALGB-40603 | Phase II random | Arm 1: T → AC Arm 2: T + Bev → AC + Bev Arm 3: T + Carbo → AC Arm 4: T + Carbo + B → AC + Bev | TNBC | Ongoing | — |
|
|
*TNBC: triple-negative breast cancer; pCR: pathological complete response; Bev: bevacizumab; T: paclitaxel; Carbo: carboplatin; D: docetaxel; C: cyclophosphamide; A: doxorubicin; E: epirubicin.
|